Anti hemagglutinin antibody market seen reaching $2.7B by 2030

The anti hemagglutinin antibody market is forecast to expand as influenza research, diagnostics and recombinant protein work accelerate. The Business Research Company projects the market will rise to $2.7 billion by 2030, with North America leading now and Asia-Pacific growing fastest.

Why it matters: - Anti hemagglutinin antibodies are used to detect, measure or isolate hemagglutinin-containing proteins in influenza research, diagnostics and vaccine development. - Growth in this market tracks broader demand for more precise diagnostic tools and standardized research reagents. - The market outlook reflects rising influenza activity and continued investment in infectious disease studies.

What happened: - The Business Research Company published its "Anti Hemagglutinin (Ha) Antibody Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report says the market rose from $1.66 billion in 2025 to $1.83 billion in 2026. - The report projects the market will reach $2.7 billion by 2030. - The report forecasts a 10.2% CAGR through 2030. - The company published a free sample of the report at the sample report. - The company also published the full report at the full market report.

The details: - Anti hemagglutinin antibodies bind specifically to the hemagglutinin protein on influenza viruses or HA-tagged recombinant proteins. - The antibodies are used across virology, molecular biology and tagged protein expression systems. - The report links recent market growth to intensified influenza research, advances in molecular biology, broader use of tagged protein systems, higher demand for diagnostic reagents and improvements in antibody engineering. - The forecast period is supported by investments in infectious disease studies, wider use of recombinant protein expression techniques, growth in diagnostic assay development, demand for standardized antibodies and innovation in antibody manufacturing. - Expected trends include higher demand for high-specificity research antibodies, broader use of recombinant antibody formats, more applications in vaccine and virology research, increased diagnostic testing and tighter attention to batch-to-batch consistency. - The report says North America held the largest market share in 2025. - The report projects Asia-Pacific will be the fastest-growing region during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - Influenza remains a major demand driver because the World Health Organization said in February 2025 that seasonal flu affects about 1 billion people globally each year. - The World Health Organization also said seasonal influenza leads to 3 million to 5 million severe cases and 290,000 to 650,000 respiratory deaths annually. - The market’s momentum suggests buyers are prioritizing tools that improve detection, monitoring and reproducibility in research workflows.

What's next: - The market is expected to keep expanding through 2030 if influenza research, diagnostics and recombinant protein applications continue to scale. - Regional growth is likely to remain strongest in Asia-Pacific, while North America stays a major market base. - The report points to continued innovation in antibody formats and manufacturing as a key driver of future demand.

The bottom line: - Anti hemagglutinin antibodies are moving from a niche research input to a growing global market tied to influenza surveillance, diagnostics and life sciences R&D.